DUBLIN, Ireland, April 27, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2017.
Quarter 1 Results
Total revenues for Q1, 2017 were $23.5m which was marginally higher than that recorded in Q1, 2016.
| 2016 Quarter 1 | 2017 Quarter 1 | Increase/ (decrease) | ||
| US$’000 | US$’000 | % | ||
| Point-of-Care | 3,268 | 4,010 | 22.7 | % |
| Clinical Laboratory | 20,248 | 19,526 | (3.6 | %) |
| Total | 23,516 | 23,536 | ||
Point-of-Care revenues for Q1, 2017 increased by $0.7m compared to Q1, 2016. This was attributable to higher HIV sales in Africa. This is reflective of the fluctuating nature of this market particularly in the context of Q1, 2016 revenues being unusually low.
Meanwhile, Clinical Laboratory revenues decreased from $20.2m to $19.5m, a decrease of 3.6% compared to Q1, 2016. This decrease was attributable to the impact of culling a range of older declining product at the end of 2016.
Gross margin for the quarter was 42%. This was a decrease when compared to the gross margin reported in Q1, 2016 of 43.1% though higher than the 40% reported in Q4, 2016. This decrease was partly due to lower production levels in the immediate aftermath of our recent product cull.
Research and Development expenses increased from $1.1m to $1.3m. Meanwhile Selling, General and Administrative (SG&A) remained constant at $7.0m.
Operating profit for the quarter decreased from $1.8m to $1.3m – due to the combined impact of the lower gross margin and slightly higher indirect costs.
Financing income for the quarter was marginally lower at $0.2m reflecting lower deposit levels and interest rates. Meanwhile, interest payable, mainly arising on the Company’s exchangeable notes, was static at $1.2m. Further non-cash income of $1m was recognised in the quarter. This was due to a gain of $1.2m arising on a decrease in the fair value of the embedded derivatives associated with the exchangeable notes and was partly offset by non-cash interest of $0.2m.
The Company recorded a profit of $1.2m for the quarter which equated to earnings per share of 5.6 cents. However, excluding non-cash items the profit for the quarter was $0.2m or an EPS of 1.0 cents. Fully diluted EPS for the quarter was 5.0 cents compared to 6.4 cents in Q1, 2016.
EBITDA before share option expense for the quarter was $2.7m.
Share Buyback
During the quarter, the Company repurchased 181,000 ADRs at an average price of $6.40 and with a total value of $1.2m. A further 134,000 ADRs at an average price of $5.63 have been repurchased since quarter end. This brings the total purchased since the beginning of the program to over 1.4m shares with a total value of $11.9m.
Comments
Commenting on the results, Kevin Tansley, Chief Financial Officer, said “Our operating profit of $1.3m this quarter was lower than the $1.8m recorded in the equivalent quarter last year due to slightly lower gross margins and marginally higher indirect costs. However, it represents a significant increase on Q4, 2016’s operating profit of $0.6m. Margins have started to rebound towards more normal levels and this will continue with revenue growth in the future, whilst indirect costs are being kept under control.”
Ronan O’Caoimh, CEO of Trinity said “We were pleased to see an improvement in profitability from the last quarter of 2016, particularly as we are now seeing the impact of culling some of our older products at the end of last year. Quarter 1 typically represents our lowest revenue quarter and we believe that future profitability growth can be achieved by concentrating on growing our key business lines with a particular emphasis on Diabetes, Autoimmunity and HIV. At the same time we will continue our share buyback program which is now approaching $12m since being initiated in 2016.”
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
| Trinity Biotech plc | |||||||||||||
| Consolidated Income Statements | |||||||||||||
| (US$000’s except share data) | Three Months Ended Mar 31, 2017 (unaudited) | Three Months Ended Mar 31, 2016 (unaudited) | Three Months Ended Dec 31, 2016 (unaudited) | ||||||||||
| Revenues | 23,536 | 23,516 | 23,681 | ||||||||||
| Cost of sales | (13,645 | ) | (13,385 | ) | (14,202 | ) | |||||||
| Gross profit | 9,891 | 10,131 | 9,479 | ||||||||||
| Gross margin % | 42.0 | % | 43.1 | % | 40.0 | % | |||||||
| Other operating income | 23 | 69 | 28 | ||||||||||
| Research & development expenses | (1,328 | ) | (1,147 | ) | (1,330 | ) | |||||||
| Selling, general and administrative expenses | (7,028 | ) | (6,961 | ) | (7,206 | ) | |||||||
| Indirect share based payments | (250 | ) | (267 | ) | (378 | ) | |||||||
| Operating profit | 1,308 | 1,825 | 593 | ||||||||||
| Financial income | 177 | 220 | 221 | ||||||||||
| Financial expenses | (1,170 | ) | (1,181 | ) | (1,182 | ) | |||||||
| Net financing (expense) | (993 | ) | (961 | ) | (850 | ) | |||||||
| Profit / (loss) before tax & non-cash financial income / (expense) | 315 | 864 | (368 | ) | |||||||||
| Income tax (expense) / credit | (99 | ) | (182 | ) | 421 | ||||||||
| Profit for the period before once-off items & non-cash financial income / (expense) | 216 | 682 | 53 | ||||||||||
| Non-cash financial income / (expense) | 1,030 | (2,029) | 4,860 | ||||||||||
| Once-off charges (net of tax) | - | | - | (105,779) | |||||||||
| Profit / (loss) after tax and once-off items | 1,246 | (1,347 | ) | (100,866 | ) | ||||||||
| Earnings / (loss) per ADR (US cents) | 5.6 | (5.8 | ) | (443.1 | ) | ||||||||
| Earnings per ADR excluding non-cash financial income (US cents)** | 1.0 | 2.9 | 0.2 | ||||||||||
| Diluted earnings per ADR (US cents) | 5.0 | 6.4* | (373.1 | ) | |||||||||
| Diluted earnings per ADR (US cents)** | 5.0 | 6.4* | 4.3 | ||||||||||
| Weighted average no. Of ADRs used in computing basic earnings per ADR | 22,102,620 | 23,287,867 | 22,761,641 | ||||||||||
| Weighted average no. Of ADRs used in computing diluted earnings per ADR | 27,362,174 | 28,656,394 | 28,031,122 | ||||||||||
* Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted earnings per ADR in quarter 1, 2016 in accordance with IFRS would be a loss of 5.8 cents (i.e. equal to basic earnings per ADR).
** Excluding once-off charges
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
| Trinity Biotech plc | |||||
| Consolidated Balance Sheets | |||||
| Mar 31, 2017 US$ ‘000 (unaudited) | Dec 31, 2016 US$ ‘000 (unaudited) | ||||
| ASSETS | |||||
| Non-current assets | |||||
| Property, plant and equipment | 14,163 | 13,403 | |||
| Goodwill and intangible assets | 88,996 | 87,275 | |||
| Deferred tax assets | 14,669 | 14,556 | |||
| Other assets | 828 | 870 | |||
| Total non-current assets | 118,656 | 116,104 | |||
| Current assets | |||||
| Inventories | 32,659 | 32,589 | |||
| Trade and other receivables | 22,683 | 22,586 | |||
| Income tax receivable | 1,290 | 1,205 | |||
| Cash and cash equivalents | 69,851 | 77,108 | |||
| Total current assets | 126,483 | 133,488 | |||
| TOTAL ASSETS | 245,139 | 249,592 | |||
| EQUITY AND LIABILITIES | |||||
| Equity attributable to the equity holders of the parent | |||||
| Share capital | 1,176 | 1,224 | |||
| Share premium | 16,122 | 16,187 | |||
| Accumulated surplus | 93,171 | 93,004 | |||
| Other reserves | (1,193 | ) | (1,688 | ) | |
| Total equity | 109,276 | 108,727 | |||
| Current liabilities | |||||
| Income tax payable | 181 | 175 | |||
| Trade and other payables | 20,893 | 25,028 | |||
| Provisions | 75 | 75 | |||
| Total current liabilities | 21,149 | 25,278 | |||
| Non-current liabilities | |||||
| Exchangeable senior note payable | 95,462 | 96,491 | |||
| Other payables | 698 | 735 | |||
| Deferred tax liabilities | 18,554 | 18,361 | |||
| Total non-current liabilities | 114,714 | 115,587 | |||
| TOTAL LIABILITIES | 135,863 | 140,865 | |||
| TOTAL EQUITY AND LIABILITIES | 245,139 | 249,592 | |||
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
| Trinity Biotech plc | ||||
| Consolidated Statement of Cash Flows | ||||
| (US$000’s) | Three Months Ended March 31, 2017 (unaudited) | Three Months Ended March 31, 2016 (unaudited) | ||
| Cash and cash equivalents at beginning of period | 77,108 | 101,953 | ||
| Operating cash flows before changes in working capital | 2,267 | 2,503 | ||
| Changes in working capital | (2,208 | ) | (628 | ) |
| Cash generated from operations | 59 | 1,875 | ||
| Net Interest and Income taxes (paid)/received | 177 | (241 | ) | |
| Capital Expenditure & Financing (net) | (3,646 | ) | (5,431 | ) |
| Free cash flow | (3,410 | ) | (3,797 | ) |
| Payment of HIV-2 licence fee | (1,112 | ) | - | |
| Share buyback | (1,833 | ) | (1,327 | ) |
| Once-off items | (902 | ) | ||
| Cash and cash equivalents at end of period | 69,851 | 96,829 | ||
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).